2026-01-27 - Analysis Report
**Company Overview:**
Amgen is a biotechnology company focused on the discovery, development, and delivery of human therapeutics.

**Comparison of Return Rate:**
Cumulative return of review stock (AMGN) = 93.67%
Cumulative return of comparison stock (S&P 500, VOO) = 127.58%
Divergence = -35.50, relative divergence = 34.90%

The return rate of AMGN is lower than the S&P 500, indicating a divergence of 35.50. However, this divergence is relatively low, especially considering the fluctuation range in the past.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|--------|
| 2016-2018  | 20.0% | 16.1% | 11.0% | 1.1  | 104.8B  |
| 2017-2019  | 45.0% | 12.1% | 20.0% | 0.9  | 129.8B  |
| 2018-2020  | 18.0% | 21.8% | -6.0% | 0.8  | 123.8B  |
| 2019-2021  | 15.0% | 21.8% | -49.0% | 0.8  | 121.1B  |
| 2020-2022  | 18.0% | 19.4% | 13.0% | 0.6  | 141.4B  |
| 2021-2023  | 21.0% | 20.6% | 3.0%  | 0.4  | 155.1B  |
| 2022-2024  | 15.0% | 21.2% | -15.0% | 0.4  | 140.3B  |
| 2023-2025  | 38.0% | 21.3% | -38.0% | 0.5  | 176.2B  |

The Alpha values indicate mixed performance across different years, but generally, the beta values are relatively low, indicating lower volatility compared to the market.

**Recent Stock Price Fluctuations:**

* Close: $349.69
* Last-market: $349.69 (change: +$4.94, +1.43%)
* 5-day SMA: $343.22
* 20-day SMA: $332.51
* 60-day SMA: $328.72

The stock price has shown a small increase over the last trading day.

**RSI, PPO, and Market Risk Indicator Analysis:**

* Market Risk Indicator (MRI): 0.70 (Medium Investment recommended)
* RSI: 71.21
* PPO: 0.64
* Hybrid Signal: Buy (Cash: 0%)
* Risk Level: Medium (MRI: 0.70)
* Recent (20 days) relative divergence change: 9.50 (+) (improving)

The Market Risk Indicator indicates a medium-risk investment, while the RSI and PPO indicators show a slight indication of overbought conditions. The stock has shown an improving relative divergence.

**Expected Return and Excess Return:**

* Expected Return (%): -30.90% (indicating potential losses)
* Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point: -30.90%

**Recent News and Significance:**

* [2026-01-26] Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks
* [2026-01-26] Intact Investment Management Inc. Cuts Stock Position in Amgen Inc. $AMGN
* [2026-01-26] UBS Raises Price Target for Amgen (AMGN) Following Recent Analysis
* [2026-01-22] Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
* [2026-01-22] Amgen stock hits 52-week high at $346.41
* [2026-01-23] SA analyst upgrades/downgrades: GE, MSFT, SMCI, AMGN

**Analyst Opinions:**

* Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 2.41 (~Buy)
  - Opinions: 27
  - Target Price (avg/high/low): $331.96 / $425.00 / $180.00

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
|--------|------|----------|
| 2025-11-05 | 5.98 | $9.56B  |
| 2025-08-06 | 2.66 | $9.18B  |
| 2025-05-02 | 3.22 | $8.15B  |
| 2024-10-31 | 5.27 | $8.50B  |
| 2025-11-05 | 5.27 | $8.50B  |

The company has consistently shown high EPS values, but the revenue growth has been steady but not exceptional.

**Financial Information:**

### Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $9.56B  | 67.75%        |
| 2025-06-30 | $9.18B  | 67.20%        |
| 2025-03-31 | $8.15B  | 63.58%        |
| 2024-12-31 | $9.09B  | 65.75%        |
| 2024-09-30 | $8.50B  | 61.07%        |

### Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $9.62B  | 33.43% |
| 2025-06-30 | $7.43B  | 19.28% |
| 2025-03-31 | $6.21B  | 27.87% |
| 2024-12-31 | $5.88B  | 10.67% |
| 2024-09-30 | $7.53B  | 37.60% |

The company has shown steady revenue growth and increasing profit margins over the quarters.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.